×
PolyPid Common Stock Net 2019-2025 | PYPD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
PolyPid common stock net from 2019 to 2025. Common stock net can be defined as the value of common equity ownership.
View More
PolyPid Common Stock Net 2019-2025 | PYPD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
PolyPid common stock net from 2019 to 2025. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$70B
Zoetis (ZTS)
$68.3B
Takeda Pharmaceutical (TAK)
$47.7B
Daiichi Sankyo, - (DSNKY)
$47.6B
BeOne Medicines - (ONC)
$35.2B
Sandoz Group AG (SDZNY)
$26.1B
Summit Therapeutics (SMMT)
$19.8B
Merck (MKKGY)
$17.1B
Shionogi (SGIOY)
$15.2B
United Therapeutics (UTHR)
$14.1B
Neurocrine Biosciences (NBIX)
$13.2B
Orion OYJ (ORINY)
$10.8B
IPSEN (IPSEY)
$10.6B
Madrigal Pharmaceuticals (MDGL)
$8.2B
Corcept Therapeutics (CORT)
$7.6B
Grifols, S.A (GRFS)
$7.4B
Ionis Pharmaceuticals (IONS)
$7B
Stevanato Group S.p.A (STVN)
$6.9B
Hikma Pharmaceuticals Plc (HKMPF)
$5.3B
Ono Pharmaceutical (OPHLF)
$5.1B
Soleno Therapeutics (SLNO)
$3.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$3B
Crinetics Pharmaceuticals (CRNX)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.8B
Hypermarcas (HYPMY)
$2.7B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.4B
Ocular Therapeutix (OCUL)
$2.2B
Endo (NDOI)
$1.8B
Dyne Therapeutics (DYN)
$1.8B